Submit your declaration of interest by the deadline to include an active substance in the EU Review Programme. The European Chemicals Agency (ECHA) has announced an opportunity for a person, company or task force/consortium to declare an interest in notifying the following active substance/product type combination to be included in the EU Review Programme. This affects NI. Â Anyone wishing to declare their interest in notifying the active substance/product type combination listed below to be included in the EU Review Programme will need to submit a declaration of interest to ECHA by the following deadline: Capsicum oleoresin expeller pressed (CAS n/a EC n/a) in product type 19
9 September 2023 If a declaration of interest to notify the active substance is not received, this active substance/product type combination will not be included in the EU Review Programme.  Biocidal products containing this active substance cannot currently be placed on the NI market. Biocidal products must be phased off the NI market The active substance/product type combinations listed below are due to expire under the EU BPR on the following dates. This affects NI: (±)-5-amino-1-(2,6-dichloro-α,α,α,-trifluoro-p-tolyl)-4-trifluoromethylsulfinylpyrazole-3-carbonitrile (1:1) (Fipronil) (CAS 120068-37-3 EC 424-610-5) in product type 18
30 September 2023
(RS)-4-hydroxy-3-(3-oxo-1-phenylbutyl)coumarin (Warfarin) (CAS 81-81-2 EC 201-377-6) in product type 14Â Â
30 June 2024
Polyhexamethylene biguanide hydrochloride with a mean number-average molecular weight (Mn) of 1600 and a mean polydispersity (PDI) of 1.8 (PHMB (1600;1.8)) (CAS 27083-27-8 / 32289-58-0 EC n/a) in product types 2, 3 and 11
30 June 2024 Once the approvals expire, the active substances can no longer be used in biocidal products of the relevant product types in NI. Â If you hold an affected EU BPR product authorisation or Control of Pesticides Regulations (COPR) product approval, we will contact you about cancelling or revoking your authorisation or approval. You will have an opportunity to submit comments or additional information and we will take account of these when finalising our decision. Â If you are aware of any disproportionate negative effects that are likely to arise from the expiry of any of the active substance/product type combinations listed above, please contact us. | 